- Home
- KNSA vs MIRM Comparison
KNSA vs MIRM Comparison
Compare KNSA & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KNSA
- MIRM
- Stock Information
- Founded
- KNSA 2015
- MIRM 2018
- Country
- KNSA United Kingdom
- MIRM United States
- Employees
- KNSA N/A
- MIRM N/A
- Industry
- KNSA Biotechnology: Pharmaceutical Preparations
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- KNSA Health Care
- MIRM Health Care
- Exchange
- KNSA Nasdaq
- MIRM Nasdaq
- Market Cap
- KNSA 1.9B
- MIRM 2.2B
- IPO Year
- KNSA 2018
- MIRM 2019
- Fundamental
- Price
- KNSA $28.44
- MIRM $50.34
- Analyst Decision
- KNSA Strong Buy
- MIRM Strong Buy
- Analyst Count
- KNSA 5
- MIRM 12
- Target Price
- KNSA $38.80
- MIRM $63.17
- AVG Volume (30 Days)
- KNSA 707.0K
- MIRM 397.8K
- Earning Date
- KNSA 07-22-2025
- MIRM 08-06-2025
- Dividend Yield
- KNSA N/A
- MIRM N/A
- EPS Growth
- KNSA N/A
- MIRM N/A
- EPS
- KNSA N/A
- MIRM N/A
- Revenue
- KNSA $481,166,000.00
- MIRM $379,251,000.00
- Revenue This Year
- KNSA $37.21
- MIRM $35.83
- Revenue Next Year
- KNSA $5.32
- MIRM $16.83
- P/E Ratio
- KNSA N/A
- MIRM N/A
- Revenue Growth
- KNSA 59.45
- MIRM 69.31
- 52 Week Low
- KNSA $17.38
- MIRM $28.56
- 52 Week High
- KNSA $30.69
- MIRM $54.23
- Technical
- Relative Strength Index (RSI)
- KNSA 55.24
- MIRM 69.78
- Support Level
- KNSA $27.62
- MIRM $48.78
- Resistance Level
- KNSA $28.69
- MIRM $50.05
- Average True Range (ATR)
- KNSA 1.13
- MIRM 1.64
- MACD
- KNSA -0.28
- MIRM 0.39
- Stochastic Oscillator
- KNSA 45.78
- MIRM 87.92
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.